More scrutiny for value-based CAR T models

A letter from Rep. Elijah Cummings (D-Md.) to Office of Management and Budget Director Mick Mulvaney on Wednesday has increased concerns that biopharmas could face greater scrutiny when negotiating value-based pricing arrangements with CMS.

Cummings cited a conflict of interest between the office's associate director, Joseph Grogan, and CMS negotiations of a proposed demonstration project by Novartis

Read the full 579 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE